Presentation is loading. Please wait.

Presentation is loading. Please wait.

Figure 1. Trial profile. From: Efficacy of high-dose alkylating chemotherapy in HER2/neu-negative breast cancer Ann Oncol. 2006;17(4):588-596. doi:10.1093/annonc/mdl001.

Published byMabel Lamb Modified over 6 years ago

Similar presentations

Presentation on theme: "Figure 1. Trial profile. From: Efficacy of high-dose alkylating chemotherapy in HER2/neu-negative breast cancer Ann Oncol. 2006;17(4):588-596. doi:10.1093/annonc/mdl001."— Presentation transcript:

1 Figure 1. Trial profile. From: Efficacy of high-dose alkylating chemotherapy in HER2/neu-negative breast cancer Ann Oncol. 2006;17(4): doi: /annonc/mdl001 Ann Oncol | © 2006 European Society for Medical Oncology

2 Figure 2. (a) RFS all 885 patients; (b) OS all 885 patients.
From: Efficacy of high-dose alkylating chemotherapy in HER2/neu-negative breast cancer Ann Oncol. 2006;17(4): doi: /annonc/mdl001 Ann Oncol | © 2006 European Society for Medical Oncology

3 Figure 3. (a) RFS HER-neg patients; (b) OS HER-neg patients.
From: Efficacy of high-dose alkylating chemotherapy in HER2/neu-negative breast cancer Ann Oncol. 2006;17(4): doi: /annonc/mdl001 Ann Oncol | © 2006 European Society for Medical Oncology

4 Figure 4. (a & b) Forest plots subgroup analyses HER2/neg tumours
Figure 4. (a & b) Forest plots subgroup analyses HER2/neg tumours. These Forest plots show the effect of high-dose therapy on the hazard ratio for relapse (or death) and the 99% confidence interval. The size of the solid squares corresponds to the size of the subgroups. Subgroups for which the line representing the 99% confidence interval lies to the left of the vertical line represent subgroups for which high-dose chemotherapy may offer a significant benefit over conventional therapy with respect to RFS. The diamonds correspond to the 95% confidence intervals. ER: oestrogen receptor; PR: progesterone receptor; MAI: mitotic activity index. From: Efficacy of high-dose alkylating chemotherapy in HER2/neu-negative breast cancer Ann Oncol. 2006;17(4): doi: /annonc/mdl001 Ann Oncol | © 2006 European Society for Medical Oncology

5 Figure 5. RFS in patients with HER2/neu-negative and hormone receptor-negative tumours.
From: Efficacy of high-dose alkylating chemotherapy in HER2/neu-negative breast cancer Ann Oncol. 2006;17(4): doi: /annonc/mdl001 Ann Oncol | © 2006 European Society for Medical Oncology

Download ppt "Figure 1. Trial profile. From: Efficacy of high-dose alkylating chemotherapy in HER2/neu-negative breast cancer Ann Oncol. 2006;17(4):588-596. doi:10.1093/annonc/mdl001."

Similar presentations

Herceptin® (trastuzumab) in combination with chemotherapy: pivotal metastatic breast cancer survival data 1.

Herceptin® (trastuzumab) in combination with chemotherapy: pivotal metastatic breast cancer survival data 1.
Clinical Relevance of HER2 Overexpression/Amplification in Patients with Small Tumor Size and Node-Negative Breast Cancer Curigliano G et al. J Clin Oncol.

Clinical Relevance of HER2 Overexpression/Amplification in Patients with Small Tumor Size and Node-Negative Breast Cancer Curigliano G et al. J Clin Oncol.
6 months versus 12 months of adjuvant trastuzumab for patients with HER2- positive early breast cancer (PHARE): a randomised phase 3 trial Speaker: 陳鴻明.

6 months versus 12 months of adjuvant trastuzumab for patients with HER2- positive early breast cancer (PHARE): a randomised phase 3 trial Speaker: 陳鴻明.
Breast cancer in elderly patients (70 years and older): The University of Tennessee Medical Center at Knoxville 10 year experience Curzon M, Curzon C,

Breast cancer in elderly patients (70 years and older): The University of Tennessee Medical Center at Knoxville 10 year experience Curzon M, Curzon C,
Rate of breast cancer-specific survival Months Low gene expression (N=252) High gene expression (N=37) P < 0.0001(Log-rank) a Months Low gene expression.

Rate of breast cancer-specific survival Months Low gene expression (N=252) High gene expression (N=37) P < (Log-rank) a Months Low gene expression.
Anastrozole (‘Arimidex’): a new standard of care?

Anastrozole (‘Arimidex’): a new standard of care?
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer Slideset on: Piccart-Gebhart M, Procter M, Leyland- Jones B, et al. Trastuzumab.

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer Slideset on: Piccart-Gebhart M, Procter M, Leyland- Jones B, et al. Trastuzumab.
Mamounas EP et al. Proc SABCS 2012;Abstract S1-10.

Mamounas EP et al. Proc SABCS 2012;Abstract S1-10.
Number of brain metastasis

Number of brain metastasis
Figure 1. FinHER dataset: distribution of tumor-infiltrating lymphocytes in breast cancer according to the (A) three breast cancer subtypes and (B) HER2.

Figure 1. FinHER dataset: distribution of tumor-infiltrating lymphocytes in breast cancer according to the (A) three breast cancer subtypes and (B) HER2.
Efficacy and Safety of Pemetrexed Maintenance Therapy versus Best Supportive Care in Patients from East Asia with Advanced, Nonsquamous Non-small Cell.

Efficacy and Safety of Pemetrexed Maintenance Therapy versus Best Supportive Care in Patients from East Asia with Advanced, Nonsquamous Non-small Cell.
Figure 1. Raw mean scores of the MFI subscales ‘mental fatigue’ and ‘reduction in motivation’ (range 4–20, the higher the score the more mental fatigue.

Figure 1. Raw mean scores of the MFI subscales ‘mental fatigue’ and ‘reduction in motivation’ (range 4–20, the higher the score the more mental fatigue.
Figure 1. Mesothelioma mortality in The Netherlands 1997–2002 (source: Netherlands National Institute of Statistics). From: Occupational asbestos exposure:

Figure 1. Mesothelioma mortality in The Netherlands 1997–2002 (source: Netherlands National Institute of Statistics). From: Occupational asbestos exposure:
Prognostic and Predictive Value of the 21-Gene Recurrence Score Assay in Postmenopausal Women with Node-Positive, Estrogen- Receptor-Positive Breast Cancer.

Prognostic and Predictive Value of the 21-Gene Recurrence Score Assay in Postmenopausal Women with Node-Positive, Estrogen- Receptor-Positive Breast Cancer.
Volume 18, Issue 7, Pages (July 2017)

Volume 18, Issue 7, Pages (July 2017)
Maximizing the Benefit-Cost Ratio of Anthracyclines in Metastatic Breast Cancer: Case Report of a Patient with a Complete Response to High-Dose Doxorubicin.

Maximizing the Benefit-Cost Ratio of Anthracyclines in Metastatic Breast Cancer: Case Report of a Patient with a Complete Response to High-Dose Doxorubicin.
Figure 1. (A) Forest plot of common odds ratios (adjusted for ECOG PS) for best overall response by a priori subgroups in patients with KRAS wild-type.

Figure 1. (A) Forest plot of common odds ratios (adjusted for ECOG PS) for best overall response by a priori subgroups in patients with KRAS wild-type.
Figure 2. A consort diagram showing the flowchart of the trial

Figure 2. A consort diagram showing the flowchart of the trial
Figure 3. Sensitivity of the gastric carcinoma cell line N87 for trastuzumab in comparison with the breast cancer cell line SKBR-3. (A) Dose–response curves.

Figure 3. Sensitivity of the gastric carcinoma cell line N87 for trastuzumab in comparison with the breast cancer cell line SKBR-3. (A) Dose–response curves.
The Evolving Standard of Care in Gastric Cancer

The Evolving Standard of Care in Gastric Cancer

Similar presentations

Ads by Google